Skip to main content
. 2021 Aug 5;11:705294. doi: 10.3389/fonc.2021.705294

Figure 1.

Figure 1

Mechanisms of action for the FDA-approved treatments for advanced/metastatic urothelial carcinoma. There are currently 6 FDA-approved agents for the treatment of MIBC, which work through diverse mechanisms, including checkpoint inhibition and blockage of the FGFR signaling pathway (16). The therapeutic agents are marked by asterisks and are in bolded boxes.